AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors
January 14th 2023A doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressing solid tumors.
Read More
Teclistamab Plus Daratumumab/Lenalidomide Generates Responses in Relapsed/Refractory Myeloma
January 13th 2023Emma Searle, PhD, provides an overview of findings from the MajesTEC-2 trial in patients with relapsed/refractory multiple myeloma, elaborates on the safety of teclistamab plus daratumumab and lenalidomide, and discusses the next steps for evaluating the combination.
Read More
COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer
January 12th 2023A triplet regimen comprised of COM701, BMS-986207, and nivolumab was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.
Read More
CDX-1140 Plus Pembrolizumab Elicits Responses in PD-1/PD-L1–Resistant Solid Tumors
January 12th 2023The utilization of the anti-CD40 agonist, CDX-1140, in combination with pembrolizumab was generally well tolerated and demonstrated preliminary efficacy in patients with anti–PD-1/PD-L1 resistant, locally advanced or metastatic solid tumors.
Read More
Chari Spotlights Efficacy of Talquetamab and Next Steps for Exploration in R/R Multiple Myeloma
January 12th 2023Ajai Chari, MD, shares some background on talquetamab, reported safety and efficacy findings from MonumenTAL-1, and highlighted other ways in which the agent is being explored in multiple myeloma.
Read More
Spira Highlights Key Advancements Across the NSCLC Treatment Paradigm in 2022
January 11th 2023Alexander Spira, MD, PhD, FACP, highlights the top advancements across non–small cell lung cancer in 2022, emphasized the need for increased genetic testing to inform treatment decisions, and previewed other agents under development.
Read More
CTLA-4–Based Combinations Highlight Evolution of Treatment in Metastatic NSCLC
January 11th 2023Vamsidhar Velcheti, MD, highlights the advancement of CTLA-4–based combinations in non–small cell lung cancer treatment, the emergence of antibody-drug conjugates in non–small cell lung cancer, and the impact of the POSEIDON trial on the treatment landscape.
Read More
Pexidartinib With Surgery Proves Potential Benefit for Patients With Tenosynovial Giant Cell Tumors
January 7th 2023R. Lor Randall, MD, FACS, discusses the outcomes of combining surgery and pexidartinib in patients with tenosynovial giant cell tumors, what investigators still need to learn about sequencing the CSF1R inhibitor around surgery, and what the combination approach could mean for patients with TGCT.
Read More
Neoadjuvant and adjuvant pertuzumab plus trastuzumab with docetaxel continued to show improvements in event-free survival, disease-free survival and overall survival vs trastuzumab/docetaxel and placebo in Asian patients with HER2-positive early or locally advanced breast cancer.
Read More
Neoadjuvant Immunotherapy Represents an Improved Option for Resectable Melanoma
December 30th 2022Anna Pavlick, DO, MBA, discusses key updates from clinical trials that continue to shape the treatment of patients with melanoma, the role of immunotherapy in the frontline setting, and the importance of toxicity management and patient support.
Read More
Physicians Turn to Molecular Profiling to Drive Treatment Decisions in Endometrial Cancer
December 29th 2022Ritu Salani, MD, MBA, discusses the continued evolution of molecular profiling in endometrial cancer, advances in immunotherapy for endometrial and cervical cancer, and ongoing research in gynecologic cancers.
Read More
Researchers Advance a Novel Screening Test for Early-Stage Ovarian and Endometrial Cancer
December 28th 2022Peter Dottino, MD, FACOG, discusses the need for more accurate early screening tests for ovarian cancer, why testing for early-stage endometrial cancer is also important, the process used to develop the screening test, and how it could be implemented into practice if it is approved by the FDA.
Read More
Doublet Combinations Could Shift Frontline Treatment Paradigm in High-Risk MDS
December 23rd 2022Guillermo Garcia-Manero, MD, discusses the exploration of these doublet therapies and what they could mean for the high-risk myelodysplastic syndromes treatment landscape, the difficulties in making strides for patients with relapsed/refractory disease, and the top highlights in myelodysplastic syndromes from the 2022 ASH Annual Meeting.
Read More
Emergence of Tebentafusp Underscores the Need for Additional Advancements in Uveal Melanoma
December 23rd 2022Richard D. Carvajal, MD, discusses the implications of the FDA approval of tebentafusp in uveal melanoma, the possibility of exploring tebentafusp in other HLA subtypes, and other areas of intriguing research in uveal melanoma.
Read More
Continued Development of Oral SERDs Could Help Reshape ER+/HER2- Breast Cancer Treatment
December 21st 2022Virginia G. Kaklamani, MD, discusses the ongoing investigation of novel oral SERDs in patients with ER-positive/HER2-negative breast cancer, the remaining unmet needs for this patient population, and ongoing trials aiming to further understand the optimal use of oral SERDs.
Read More
Sacituzumab Govitecan, Trastuzumab Deruxtecan Highlight Expanding Role of ADCs in TNBC
December 17th 2022Nour Abuhadra, MD, discusses what the data from DESTINY-Breast04 means for trastuzumab deruxtecan in the triple-negative breast cancer space and future areas of research for antibody-drug conjugates in this disease.
Read More
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
December 7th 2022Non-Hispanic Black patients with hormone receptor–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, according to an analysis of the phase 3 RxPONDER trial.
Read More
Zimberelimab Monotherapy Elicits Responses in PD-L1–Positive Recurrent or Metastatic Cervical Cancer
December 1st 2022Zimberelimab monotherapy demonstrated durable responses and was well tolerated in patients with PD-L1–positive, recurrent or metastatic cervical cancer who had progressed after first- or subsequent-line, platinum-containing chemotherapy, according to data from a phase 2 trial.
Read More
ADCs Represent One of Many Improvements in GU Cancer Treatment
November 28th 2022Daniel J. George, MD, discusses the impact that ADCs have had on the evolving treatment landscape of bladder cancer, long-term outcomes with immunotherapy in metastatic renal cell carcinoma, and highlighted current and ongoing research at the Duke Cancer Institute.
Read More
Halmos Highlights Immunotherapy Treatment Decisions, Emerging ADCs in NSCLC
November 25th 2022Balazs Halmos, MD, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer.
Read More
Standard Induction Evolves in Transplant-Eligible and -Ineligible Multiple Myeloma
November 16th 2022Shambavi Richard, MD, discussed key studies that continue to shape the SOC in both the transplant-eligible and -ineligible populations, the role of transplant in the space, and unmet needs that remain for older and frail patients.
Read More
Mirvetuximab Soravtansine Leads a Cascade of ADCs Under Development in Ovarian Cancer
November 7th 2022Kathleen N. Moore, MD, MS, discusses the clinical implications of the potential FDA approval of mirvetuximab soravtansine, observations from other antibody-drug conjugates under investigation in clinical trials, and the rationale of examining PARP inhibitor–based combinations in ovarian cancer.
Read More
Tivozanib Maintains Long-Term PFS Benefit Over Sorafenib in Relapsed/Refractory RCC
November 5th 2022Tivozanib continued to display a progression-free survival benefit and rates vs sorafenib in patients with relapsed/refractory renal cell carcinoma who received 2 or 3 prior systemic regimens.
Read More